Osiris Therapeutics, Inc. (OSIR)

18.99
NASDAQ
Prev Close 18.99
Day Low/High 0.00 / 0.00
52 Wk Low/High 7.30 / 19.30
Exchange NASDAQ
Div & Yield N.A. (N.A)
OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces An Investigation Of Osiris Therapeutics, Inc. (OSIR) Over The Proposed Merger Of The Company With Smith & Nephew Plc

OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces An Investigation Of Osiris Therapeutics, Inc. (OSIR) Over The Proposed Merger Of The Company With Smith & Nephew Plc

NEW YORK, March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc.

Lifshitz & Miller LLP Announces Investigation Of Amarin Corporation Plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., And The Kraft Heinz Company

Lifshitz & Miller LLP Announces Investigation Of Amarin Corporation Plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., And The Kraft Heinz Company

NEW YORK, March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

NEW YORK, March 15, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Osiris Therapeutics, Inc. - OSIR

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Osiris Therapeutics, Inc. - OSIR

NEW YORK, March 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Osiris Therapeutics, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Osiris Therapeutics, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Osiris Therapeutics, Inc.

NEW YORK, March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc.

Smith & Nephew Expands In High Growth Regenerative Medicine Market Through Acquisition Of Osiris Therapeutics, Inc.

Smith & Nephew Expands In High Growth Regenerative Medicine Market Through Acquisition Of Osiris Therapeutics, Inc.

LONDON, March 12, 2019 /PRNewswire/ -- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMKR, ANF, C, HOLI, MIDD, OI, OSIR, OSIS, PNRG, RMR, SNX, SVVC, TAL Downgrades: ESND, NEP, STRT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Hagens Berman: Notice To Osiris Therapeutics, Inc. Investors: Less Than One Week Left To File Claims To Receive Part Of $18.5 Million Settlement

Hagens Berman: Notice To Osiris Therapeutics, Inc. Investors: Less Than One Week Left To File Claims To Receive Part Of $18.5 Million Settlement

National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached an $18.

Hagens Berman Notifies Osiris Therapeutics, Inc. Investors Of Class Action Settlement And January 30, 2019 Claims Deadline

Hagens Berman Notifies Osiris Therapeutics, Inc. Investors Of Class Action Settlement And January 30, 2019 Claims Deadline

National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached a settlement on behalf of investors in Osiris Therapeutics, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, OSIR Downgrades: UBA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Notable Two Hundred Day Moving Average Cross - OSIR

Notable Two Hundred Day Moving Average Cross - OSIR

In trading on Wednesday, shares of Osiris Therapeutics Inc crossed below their 200 day moving average of $7.86, changing hands as low as $7.40 per share. Osiris Therapeutics Inc shares are currently trading off about 5% on the day.

Osiris Therapeutics Enters Oversold Territory (OSIR)

Osiris Therapeutics Enters Oversold Territory (OSIR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Osiris Therapeutics To Present 10 Advanced Clinical And Scientific Abstracts, Including An Exclusive Oral Presentation On Its New Ambient Viable Tissue Preservation Technology

Osiris Therapeutics To Present 10 Advanced Clinical And Scientific Abstracts, Including An Exclusive Oral Presentation On Its New Ambient Viable Tissue Preservation Technology

Experts to host a variety of presentations at Symposium on Advanced Wound Care Fall Meeting, October 20 - October 22, 2017, in Las Vegas, Nevada

Osiris Therapeutics To Present 29 Advanced Clinical And Scientific Abstracts, Including A Late-Breaking Abstract On Its New Ambient Viable Tissue Preservation Technology

Experts to host a variety of presentations at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference, April 5 - April 9, 2017, in San Diego, California

Osiris Therapeutics, Inc. Completes Restatement Of 2014 Financial Statements

Osiris also Reports Preliminary Estimated 2015 and 2016

Osiris Therapeutics Becomes Oversold (OSIR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Thursday Option Activity: OSIR, UTHR, FIZZ

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Osiris Therapeutics Inc , where a total volume of 1,040 contracts has been traded thus far today, a contract volume which is representative of approximately 104,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 112.8% of OSIR's average daily trading volume over the past month, of 92,220 shares.